Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Anaplastic thyroid cancer Stories

2012-06-21 02:14:41

A molecule widely believed to fight many forms of cancer actually helps deadly thyroid tumors grow, and cancer therapies now being tested in humans might boost the activity of this newly revealed bad guy, researchers at Mayo Clinic in Florida say. Their findings are published online this month in the Journal of Cell Science. The study found that in anaplastic thyroid cancer, the Forkhead transcription factor, FOXO3a, is not the helpful tumor suppressor everyone thought it was, but,...

2012-01-22 12:00:00

REYKJAVIK, Iceland, January 22, 2012 /PRNewswire/ -- Scientists at deCODE Genetics and academic collaborators from Iceland, the USA, The Netherlands and Spaintoday report the discovery of variants in the human genome that associate with levels of thyroid stimulating hormone and risk of thyroid cancer.The paper 'Discovery of common variants associated with low TSH levels and thyroid cancer risk' is published today in the online edition of Nature Genetics. Using data...

2011-11-05 01:21:46

The combination of chemotherapy and radiation significantly improved the 5-year overall survival of patients with stage II nasopharyngeal carcinoma (NPC), according to a phase III study published Nov. 4 in the Journal of the National Cancer Institute. Nasopharyngeal carcinoma is endemic in Southern China and Southeast Asia, where radiotherapy (RT) has been the primary treatment. Although the National Comprehensive Cancer Network (NCCN) recommends concurrent chemo-radiotherapy (CCRT) for...

2010-09-22 09:51:39

(Ivanhoe Newswire) -- The results are in.  After a phase 2 trial, 49 percent of patients with advanced differentiated thyroid cancers responded to treatment using a drug designed to stop tumor blood vessel growth.  The name of drug that has shown the highest response of any treatment to date for advanced thyroid cancer: pazopanib.  The estimated time two-thirds of these patients are likely to have a response to the drug: 1 year or longer.  With the incidence of thyroid...

2010-09-20 18:39:44

Given potential side effects, patients with slow-growing thyroid cancer should not use pazopanib The drug pazopanib may help revolutionize the care of patients with metastatic, rapidly progressive differentiated thyroid cancers, say researchers at Mayo Clinic who are publishing findings of a phase II clinical trial in The Lancet Oncology. VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Keith Bible describing the research, are available on the...

2010-08-25 14:23:33

To their deep dismay, researchers at Mayo Clinic discovered several years ago that laboratory samples of anaplastic thyroid cancer (ATC) they were using to help them find new treatments for this lethal disease were probably some other kind of cancer. It quickly became evident that the situation in their lab was common throughout the world. Up to half of the cell lines that were supposed to originate from patients with this rare thyroid cancer were either colon or melanoma cancer. So, with the...

2010-05-27 10:32:09

Researchers at Mayo Clinic say a nationwide clinical trial is also planned Aggressive treatment of anaplastic thyroid carcinoma has dramatically increased survival in the small group of patients who chose to undergo it, say physicians at Mayo Clinic. Their findings will be presented at the annual meeting of the American Society of Clinical Oncology, to be held June 4-8 in Chicago. Mayo oncologists say this new approach reflects the need to aggressively treat metastasis even when this rare...

2009-09-22 07:10:39

Medicare recipients with head and neck cancer commonly do not complete radiation therapy without interruptions or at all, according to a report in the September issue of Archives of Otolaryngology"“Head & Neck Surgery, one of the JAMA/Archives journals. Patients who have surgery before radiation treatment appear more likely to complete therapy, whereas those who have other illnesses or who have chemotherapy first may be more likely to experience interruptions or discontinuation in...

2009-01-20 12:35:23

U.S. scientists have found an experimental anaplastic thyroid cancer drug can activate a powerful tumor suppressor that has the ability to halt cell growth. Researchers at the Mayo Clinic campus in Jacksonville, Fla., say few other cancer drugs have that ability and the drug, called RS5444, might be useful in treating other cancers. The researchers found human anaplastic thyroid tumor cells treated with RS5444 expressed a protein known as p21, which inhibited cell replication and tumor...

2009-01-20 11:18:50

Researchers at Mayo Clinic have found that the experimental drug they are testing to treat a deadly form of thyroid cancer turns on a powerful tumor suppressor capable of halting cell growth. Few other cancer drugs have this property, they say. In the Feb. 15 issue of Cancer Research (available online Jan. 20), they report that RS5444, being tested in a Phase 1/2 clinical trial to treat anaplastic thyroid cancer, might be useful for treating other cancers. The agent is also known as CS-7017....